Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213759 | 0.88 | RAB9A (0.52) | HTTALDH1A1MAPTNPC1POLB | |
| SCHEMBL27213679 | 0.84 | MAOB (0.48) | ALDH1A1MAPTNPC1POLBRAB9A | |
| SCHEMBL29322169 | 0.83 | PARP10 (0.54) | HTTALDH1A1MAPTNPC1POLB | |
| SCHEMBL31578969 | 0.78 | RAB9A (0.52) | HTTALDH1A1MAPTNPC1POLB | |
| SCHEMBL29318864 | 0.78 | POLB (0.42) | HTTLMNAALDH1A1MAPTNPC1 | |
| SCHEMBL27213716 | 0.78 | P2RX7 (0.39) | HTTALDH1A1MAPT | |
| SCHEMBL30995292 | 0.78 | POLB (0.42) | HTTLMNAALDH1A1MAPTNPC1 | |
| SCHEMBL27390891 | 0.78 | P2RX7 (0.39) | HTTALDH1A1MAPT | |
| SCHEMBL14776103 | 0.77 | ROCK2 (0.38) | HTTLMNAALDH1A1POLBPARP10 | |
| SCHEMBL29318811 | 0.77 | POLB (0.43) | HTTLMNAALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598908-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | Pfizer Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024075051-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | HTT 883/4885LMNA 1598/4885ALDH1A1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.